CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. Between 74-89% of retail investor accounts lose money when trading CFDs. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money. Please refer to our Risk Disclosure Statement
Open platformOpen platform

Gilead’s Livdelzi meets ALP normalization endpoint in 75.4% of patients in Phase 3 PBC trial

By Public Technologies
  • Gilead Sciences reported Phase 3 IDEAL results showing Livdelzi normalized a key liver disease marker more often than placebo in primary biliary cholangitis.
  • The trial evaluated second-line treatment in patients with mildly elevated alkaline phosphatase levels, a population largely excluded from previous pivotal trials.
  • No new safety concerns emerged; adverse event rates were generally similar between treatment groups.
  • Gilead is discussing the results with global regulators.
  • Results will be presented at The Liver Meeting in Denver, November 5-9, 2026; publication has been accepted by the Journal of Hepatology.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Gilead Sciences Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20261104536872) on November 05, 2026, and is solely responsible for the information contained therein.

Capital Com is an execution-only service provider. The present material must be regarded as marketing communication and should not be interpreted as investment research or investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. If you rely on the information on this page, then you do so entirely at your own risk